These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 9690172)
21. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate. Senkovich O; Schormann N; Chattopadhyay D Acta Crystallogr D Biol Crystallogr; 2009 Jul; 65(Pt 7):704-16. PubMed ID: 19564691 [TBL] [Abstract][Full Text] [Related]
22. Molecular dynamics of interactions between rigid and flexible antifolates and dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant Plasmodium falciparum. Mokmak W; Chunsrivirot S; Hannongbua S; Yuthavong Y; Tongsima S; Kamchonwongpaisan S Chem Biol Drug Des; 2014 Oct; 84(4):450-61. PubMed ID: 24716467 [TBL] [Abstract][Full Text] [Related]
23. Comparative activity of rat liver dihydrofolate reductase with 7,8-dihydrofolate and other 7,8-dihydropteridines. Webber S; Whiteley JM Arch Biochem Biophys; 1985 Feb; 236(2):681-90. PubMed ID: 3970530 [TBL] [Abstract][Full Text] [Related]
26. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase. Fogel GB; Cheung M; Pittman E; Hecht D J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315 [TBL] [Abstract][Full Text] [Related]
27. FlexE: efficient molecular docking considering protein structure variations. Claussen H; Buning C; Rarey M; Lengauer T J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774 [TBL] [Abstract][Full Text] [Related]
28. Halogenated derivatives of methotrexate as human dihydrofolate reductase inhibitors in cancer chemotherapy. Uddin N; Ahmed S; Khan AM; Mazharol Hoque M; Halim MA J Biomol Struct Dyn; 2020 Feb; 38(3):901-917. PubMed ID: 30938661 [TBL] [Abstract][Full Text] [Related]
29. Towards understanding the mechanisms of molecular recognition by computer simulations of ligand-protein interactions. Verkhivker GM; Rejto PA; Bouzida D; Arthurs S; Colson AB; Freer ST; Gehlhaar DK; Larson V; Luty BA; Marrone T; Rose PW J Mol Recognit; 1999; 12(6):371-89. PubMed ID: 10611647 [TBL] [Abstract][Full Text] [Related]
30. Importance of substrate and cofactor polarization in the active site of dihydrofolate reductase. Garcia-Viloca M; Truhlar DG; Gao J J Mol Biol; 2003 Mar; 327(2):549-60. PubMed ID: 12628257 [TBL] [Abstract][Full Text] [Related]
31. Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry. Cody V; Luft JR; Pangborn W; Gangjee A; Queener SF Acta Crystallogr D Biol Crystallogr; 2004 Apr; 60(Pt 4):646-55. PubMed ID: 15039552 [TBL] [Abstract][Full Text] [Related]
32. Identification of the optimal third generation antifolate against P. falciparum and P. vivax. Hunt SY; Detering C; Varani G; Jacobus DP; Schiehser GA; Shieh HM; Nevchas I; Terpinski J; Sibley CH Mol Biochem Parasitol; 2005 Dec; 144(2):198-205. PubMed ID: 16181688 [TBL] [Abstract][Full Text] [Related]
33. 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. Rosowsky A; Mota CE; Queener SF; Waltham M; Ercikan-Abali E; Bertino JR J Med Chem; 1995 Mar; 38(5):745-52. PubMed ID: 7877140 [TBL] [Abstract][Full Text] [Related]
34. Towards a MIP-based alignment and docking in computer-aided drug design. Barbany M; Gutiérrez-de-Terán H; Sanz F; Villà-Freixa J Proteins; 2004 Aug; 56(3):585-94. PubMed ID: 15229890 [TBL] [Abstract][Full Text] [Related]
35. Investigating the selectivity of potential new inhibitors of dihydrofolate reductase from Yersinia pestis designed by molecular modeling. Bastos LDC; de Souza FR; Pereira Souza LM; Forgione P; Cuya T; de Alencastro RB; Pimentel AS; Celmar Costa França T J Biomol Struct Dyn; 2019 Mar; 37(5):1170-1176. PubMed ID: 29542379 [No Abstract] [Full Text] [Related]
36. The crystal structure of dihydrofolate reductase from Thermotoga maritima: molecular features of thermostability. Dams T; Auerbach G; Bader G; Jacob U; Ploom T; Huber R; Jaenicke R J Mol Biol; 2000 Mar; 297(3):659-72. PubMed ID: 10731419 [TBL] [Abstract][Full Text] [Related]
37. Studies on the mechanism of antifolate induced inhibition on HeLa cell growth. Pristoupilová K; Hermanová E; Slavík K Biochem Pharmacol; 1973 Aug; 22(15):1937-42. PubMed ID: 4722461 [No Abstract] [Full Text] [Related]
38. Nonadditivity of mutational effects at the folate binding site of Escherichia coli dihydrofolate reductase. Huang Z; Wagner CR; Benkovic SJ Biochemistry; 1994 Sep; 33(38):11576-85. PubMed ID: 7918371 [TBL] [Abstract][Full Text] [Related]
39. Free energy force field (FEFF) 3D-QSAR analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors. Santos-Filho OA; Mishra RK; Hopfinger AJ J Comput Aided Mol Des; 2001 Sep; 15(9):787-810. PubMed ID: 11776291 [TBL] [Abstract][Full Text] [Related]
40. Flexible diaminodihydrotriazine inhibitors of Plasmodium falciparum dihydrofolate reductase: Binding strengths, modes of binding and their antimalarial activities. Kamchonwongpaisan S; Charoensetakul N; Srisuwannaket C; Taweechai S; Rattanajak R; Vanichtanankul J; Vitsupakorn D; Arwon U; Thongpanchang C; Tarnchompoo B; Vilaivan T; Yuthavong Y Eur J Med Chem; 2020 Jun; 195():112263. PubMed ID: 32294614 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]